Ranbaxy's Discovery Unit To Move Into Daiichi Sankyo's Global R&D Structure To Create New Drugs Faster
This article was originally published in The Pink Sheet Daily
Executive Summary
Ranbaxy will continue its discovery collaboration with GSK, pursue its Phase III in-house anti-malarial program, and sharpen its focus on generics R&D.